dizocilpine-maleate and 3-aminobenzamide

Recombinant tissue plasminogen activator (rt-PA) treatment improves functional outcome after acute ischemic stroke, inducing reperfusion by its thrombolytic activity. Conversely, there is evidence that rt-PA can mediate neuronal damage after ischemic brain injury in vivo. In addition to other mechanisms, enhancement of N-methyl-D-aspartate (NMDA) receptor signalling has been proposed to underlie rt-PA-mediated neurotoxicity. However, the role of poly(ADP-ribose) polymerase-1 (PARP-1) activation, which mediates postischemic excitotoxic cell death, in rt-PA-mediated aggravation of ischemic brain injury has not been established and was therefore addressed in this study. After permanent focal cerebral ischemia, intravenous rt-PA application significantly increased early postischemic PARP-1 activation within ischemic hemispheres and infarct volumes compared with control mice without affecting cerebral blood flow. Rt-PA induced increase in PARP-1 activation, and infarct volumes could be blocked by the PARP inhibitor 3-aminobenzamide. Moreover, the rt-PA-induced increase in PARP-1 activation was also prevented by the NMDA antagonist MK-801. In summary, we demonstrate that rt-PA treatment enhances postischemic PARP-1 activation, which contributes to rt-PA induced aggravation of ischemic brain injury in vivo. Furthermore, we provide evidence that NMDA receptor activation is required for rt-PA-mediated effects on postischemic PARP-1 activation.

Topics: Animals; Benzamides; Blood Gas Analysis; Blood Pressure; Blood-Brain Barrier; Brain; Brain Infarction; Brain Ischemia; Dizocilpine Maleate; Enzyme Activation; Ischemic Attack, Transient; Male; Mice; Mice, Inbred C57BL; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Receptors, N-Methyl-D-Aspartate; Recombinant Proteins; Tissue Plasminogen Activator

Excessive activation of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme that is activated by DNA damage, leads to neuronal cell death through depletion of ATP. The purpose of this study was to determine whether inhibition of PARP has some neuroprotective effects on the N-methyl-D-aspartate (NMDA)-induced functional and morphological injury to the rabbit retina.. Visually evoked potentials (VEPs) were recorded at different times after an intravitreal injection of NMDA (200, 660, and 2000 nmol) alone, or NMDA with 3-aminobenzamide (ABA, 200 nmol), a PARP inhibitor, or with MK-801 (200 nmol), an NMDA antagonist. The physiological changes were followed for 2 weeks, after which the eyes were enuculeated and prepared for histological examinations.. Intravitreal injections of NMDA reduced the amplitudes of rabbit VEPs and the number of cells in the retinal ganglion cell layer in a dose-dependent manner. No significant changes could be detected in the bright-flash electroretinograms (ERGs). Simultaneous injection of MK-801 (200 nmol) significantly diminished the changes induced by intravitreal NMDA. 3-Aminobenzamide (ABA) (200 nmol) also suppressed these changes, but its effects were less than those of MK-801.. NMDA-induced retinal damage can be detected by VEPs, and PARP inhibition has some neuroprotective effects on the NMDA-induced retinal damage.

Topics: Animals; Benzamides; Cell Count; Cytoprotection; Dizocilpine Maleate; Dose-Response Relationship, Drug; Electroretinography; Enzyme Activation; Enzyme Inhibitors; Evoked Potentials, Visual; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Immunoenzyme Techniques; Injections; N-Methylaspartate; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rabbits; Retina; Retinal Diseases; Retinal Ganglion Cells; Vitreous Body